Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 5/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862341 | 0.95 | PPARG (0.40) | PPARGF2RL3SERPINE1ABL1CYP2C8 | |
| SCHEMBL862496 | 0.94 | PPARG (0.38) | PPARGF2RL3SERPINE1CYP2C8BRD4 | |
| SCHEMBL862899 | 0.94 | PPARG (0.42) | PPARGF2RL3CYP2C8BRD4FBP1 | |
| SCHEMBL862753 | 0.92 | PPARG (0.38) | PPARGF2RL3SERPINE1CYP2C8BRD4 | |
| SCHEMBL862323 | 0.91 | PPARG (0.42) | PPARGCYP2C8EPHX2 | |
| SCHEMBL862501 | 0.91 | PPARG (0.47) | PPARGSERPINE1ABL1 | |
| SCHEMBL862897 | 0.90 | PPARG (0.37) | PPARGSERPINE1CYP2C8BRD4 | |
| SCHEMBL10254940 | 0.90 | CYP2C8 (0.38) | PPARGCYP2C8BRD4 | |
| SCHEMBL10257342 | 0.90 | SERPINE1 (0.43) | PPARGF2RL3SERPINE1ABL1CYP2C8 | |
| SCHEMBL10255442 | 0.90 | F2RL3 (0.39) | PPARGF2RL3SERPINE1ABL1CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| WO-2009032116-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | PPARG 4093/4885F2RL3 1782/4885SERPINE1 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.